Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer

ABSTRACT: Study to evaluate the anti-tumour activity, safety and pharmacokinetics of unlabelled sibrotuzumab administered weekly (seven days +/- one day) at a dose of 100 mg (a total of 12 administrations) in patients with metastatic colorectal cancer.

DISEASE(S): Colorectal Neoplasms

PROVIDER: 2171181 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR